Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Dyne Therapeutics reported significant advancements in its muscle disease therapeutics, particularly in its DM1, DMD, and FSHD programs. The company announced a net loss of $28.6 million for Q4 2020 and $59.4 million for the full year, with cash reserves of $345.3 million expected to last into H2 2024. Recent preclinical data showed robust RNA knockdown capabilities in their DM1 candidate. Additionally, leadership enhancements and a successful public offering raised over $550 million in 2020, supporting ongoing clinical developments.
- Raised over $550 million through IPO and public offerings in 2020.
- Cash runway extended into the second half of 2024.
- Successful preclinical data demonstrating significant RNA knockdown in DM1 program.
- Net loss increased to $28.6 million in Q4 2020, compared to $5.4 million in Q4 2019.
- Full-year net loss of $59.4 million represents a significant increase from $14.9 million in 2019.
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -
- Recent Appointments to Experienced Leadership Team Strengthen Company's Clinical Development Capabilities -
- Successful Financings Expected to Provide Cash Runway into the Second Half of 2024 -
WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2020 and recent business highlights.
“2020 was a transformational year for Dyne. We delivered validating data for our FORCE™ platform and programs, further strengthened our exceptional team with the addition of highly experienced leaders and completed our IPO. Together with earlier financings in 2020 and the follow-on public offering completed in January 2021, we have raised more than
Recent Highlights
- In January 2021, Dyne announced new preclinical data from its myotonic dystrophy type 1 (DM1) program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease. To assess the ability of its lead DM1 candidate to reduce toxic human nuclear DMPK RNA, Dyne developed an innovative hTfR1/DMSXL mouse model that expresses the human TfR1 (hTfR1) and carries a human DMPK gene that represents a severe DM1 phenotype with more than 1,000 CTG repeats. In this model, two doses (2 x 10 mg/kg) of Dyne’s candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days: 60 percent in the heart; 56 percent in the diaphragm; 54 percent in the tibialis anterior and 39 percent in the gastrocnemius. In the study, Dyne’s candidate was well tolerated. Dyne expects to share data from the hTfR1/DMSXL model at a scientific meeting during 2021.
- The Company further strengthened its leadership team with the appointment of Wildon Farwell, M.D., MPH, as chief medical officer, announced separately today, and Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs, in February 2021.
- In January 2021, Dyne completed its follow-on public offering of 6,000,000 shares of its common stock at a public offering price of
$28.00 per share. Gross proceeds of the offering before deducting the underwriting discount and commissions and offering expenses were approximately$168 million . Dyne expects its cash, cash equivalents and marketable securities as of December 31, 2020, together with the net proceeds from the January 2021 public offering, will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2024.
Upcoming Scientific & Investor Conference Presentations
- Dyne is scheduled to participate in the 2021 MDA Virtual Clinical & Scientific Conference. Romesh Subramanian, Ph.D., chief scientific officer, will present as part of the panel “Therapeutic Considerations for Dominant Neuromuscular Diseases,” and Oxana Beskrovnaya, Ph.D., senior vice president, head of research, will participate in the “Non-viral Delivery in Neuromuscular Disease” session. Both presentations will take place on March 15, 2021 and will be available to registered attendees at: https://mdavirtualconference.org/.
- Dr. Beskrovnaya also intends to present on Dyne’s FORCE platform during the virtual 7th Cold Spring Harbor Laboratory meeting on Nucleic Acid Therapies on March 24, 2021, which is accessible to registered participants at: https://meetings.cshl.edu/meetings.aspx?meet=NAT&year=21.
- Mr. Brumm and Dr. Subramanian are scheduled to participate in a virtual fireside chat during Stifel’s 3rd Annual CNS Day on April 1, 2021 at 10:30 am ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the presentation.
Fourth Quarter and Full Year 2020 Financial Results
Cash position: Cash, cash equivalents and marketable securities were
Research and development (R&D) expenses: R&D expenses were
General and administrative (G&A) expenses: G&A expenses were
Net loss: Net loss for the quarter ended December 31, 2020 was
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects, plans, objectives of management, the expected timeline for submitting investigational new drug applications and achieving proof-of-concept data readouts and the sufficiency of its cash resources, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to submit investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties related to Dyne’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements for the anticipated periods; the impact of the COVID-19 pandemic on Dyne’s business and operations; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
| Dyne Therapeutics, Inc. | ||||||||||||||||
| Condensed Consolidated Statement of Operations | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 22,098 | $ | 4,259 | $ | 45,200 | $ | 11,040 | ||||||||
| General and administrative | 6,502 | 1,211 | 13,447 | 2,786 | ||||||||||||
| Total operating expenses | 28,600 | 5,470 | 58,647 | 13,826 | ||||||||||||
| Loss from operations | (28,600 | ) | (5,470 | ) | (58,647 | ) | (13,826 | ) | ||||||||
| Other (expense) income | (49 | ) | 67 | (790 | ) | (1,033 | ) | |||||||||
| Net loss | $ | (28,649 | ) | $ | (5,403 | ) | $ | (59,437 | ) | $ | (14,859 | ) | ||||
| Net loss per share—basic and diluted | $ | (0.64 | ) | $ | (2.10 | ) | $ | (4.13 | ) | $ | (6.08 | ) | ||||
| Weighted-average common shares outstanding used in net loss per share—basic and diluted | 45,058,494 | 2,567,007 | 14,395,955 | 2,442,872 | ||||||||||||
| Dyne Therapeutics, Inc. | ||||||
| Condensed Consolidated Balance Sheet Data | ||||||
| (in thousands) | ||||||
| December 31, | December 31, | |||||
| 2020 | 2019 | |||||
| Assets | ||||||
| Cash, cash equivalents and marketable securities | $ | 345,314 | $ | 14,632 | ||
| Other assets | 8,020 | 1,804 | ||||
| Total assets | $ | 353,334 | $ | 16,436 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Liabilities | 10,967 | 2,400 | ||||
| Stockholders’ equity | 342,367 | 14,036 | ||||
| Total liabilities and stockholders’ equity | $ | 353,334 | $ | 16,436 | ||
FAQ
What were Dyne Therapeutics' financial results for Q4 2020?
How much cash does Dyne Therapeutics have as of December 31, 2020?
What is the focus of Dyne Therapeutics' programs?
When does Dyne Therapeutics expect its cash runway to last until?
What significant data was reported for Dyne's DM1 program?
